The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.

Since late January, The Times has tracked cases of coronavirus in real time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.

We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists and government officials who would like access to the data to better understand the outbreak.

The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.

As of March 10, 2023, there have been 1.1 million deaths related to COVID-19 in the United States. There have been 101,159 deaths in the state of California, more than any other state in the country – California is also the state with the highest number of COVID-19 cases.

The vaccine rollout in the U.S. Since the start of the pandemic, the world has eagerly awaited the arrival of a safe and effective COVID-19 vaccine. In the United States, the immunization campaign started in mid-December 2020 following the approval of a vaccine jointly developed by Pfizer and BioNTech. As of March 22, 2023, the number of COVID-19 vaccine doses administered in the U.S. had reached roughly 673 million. The states with the highest number of vaccines administered are California, Texas, and New York.

Vaccines achieved due to work of research groups Chinese authorities initially shared the genetic sequence to the novel coronavirus in January 2020, allowing research groups to start studying how it invades human cells. The surface of the virus is covered with spike proteins, which enable it to bind to human cells. Once attached, the virus can enter the cells and start to make people ill. These spikes were of particular interest to vaccine manufacturers because they hold the key to preventing viral entry.

Updates

• Notice of data discontinuation: Since the start of the pandemic, AP has reported case and death counts from data provided by Johns Hopkins University. Johns Hopkins University has announced that they will stop their daily data collection efforts after March 10. As Johns Hopkins stops providing data, the AP will also stop collecting daily numbers for COVID cases and deaths. The HHS and CDC now collect and visualize key metrics for the pandemic. AP advises using those resources when reporting on the pandemic going forward.

  • CDC Weekly case and death counts (national and state level)
  • CDC County level cases and deaths
  • HHS New hospital admissions
  • CDC NowCast COVID variant proportions (national and regional level)

• April 9, 2020

  • The population estimate data for New York County, NY has been updated to include all five New York City counties (Kings County, Queens County, Bronx County, Richmond County and New York County). This has been done to match the Johns Hopkins COVID-19 data, which aggregates counts for the five New York City counties to New York County.

• April 20, 2020

  • Johns Hopkins death totals in the US now include confirmed and probable deaths in accordance with CDC guidelines as of April 14. One significant result of this change was an increase of more than 3,700 deaths in the New York City count. This change will likely result in increases for death counts elsewhere as well. The AP does not alter the Johns Hopkins source data, so probable deaths are included in this dataset as well.

• April 29, 2020

  • The AP is now providing timeseries data for counts of COVID-19 cases and deaths. The raw counts are provided here unaltered, along with a population column with Census ACS-5 estimates and calculated daily case and death rates per 100,000 people. Please read the updated caveats section for more information.

• September 1st, 2020

  • Johns Hopkins is now providing counts for the five New York City counties individually.

• February 12, 2021

  • The Ohio Department of Health recently announced that as many as 4,000 COVID-19 deaths may have been underreported through the state’s reporting system, and that the "daily reported death counts will be high for a two to three-day period."
  • Because deaths data will be anomalous for consecutive days, we have chosen to freeze Ohio's rolling average for daily deaths at the last valid measure until Johns Hopkins is able to back-distribute the data. The raw daily death counts, as reported by Johns Hopkins and including the backlogged death data, will still be present in the new_deaths column.

• February 16, 2021

  - Johns Hopkins has reconciled Ohio's historical deaths data with the state.

  Overview

The AP is using data collected by the Johns Hopkins University Center for Systems Science and Engineering as our source for outbreak caseloads and death counts for the United States and globally.

The Hopkins data is available at the county level in the United States. The AP has paired this data with population figures and county rural/urban designations, and has calculated caseload and death rates per 100,000 people. Be aware that caseloads may reflect the availability of tests -- and the ability to turn around test results quickly -- rather than actual disease spread or true infection rates.

This data is from the Hopkins dashboard that is updated regularly throughout the day. Like all organizations dealing with data, Hopkins is constantly refining and cleaning up their feed, so there may be brief moments where data does not appear correctly. At this link, you’ll find the Hopkins daily data reports, and a clean version of their feed.

The AP is updating this dataset hourly at 45 minutes past the hour.

To learn more about AP's data journalism capabilities for publishers, corporations and financial institutions, go here or email kromano@ap.org.

Queries

Use AP's queries to filter the data or to join to other datasets we've made available to help cover the coronavirus pandemic

• Filter cases by state here

• Rank states by their status as current hotspots. Calculates the 7-day rolling average of new cases per capita in each state: https://data.world/associatedpress/johns-hopkins-coronavirus-case-tracker/workspace/query?queryid=481e82a4-1b2f-41c2-9ea1-d91aa4b3b1ac

• Find recent hotspots within your state by running a query to calculate the 7-day rolling average of new cases by capita in each county: https://data.world/associatedpress/johns-hopkins-coronavirus-case-tracker/workspace/query?queryid=b566f1db-3231-40fe-8099-311909b7b687&showTemplatePreview=true

• Join county-level case data to an earlier dataset released by AP on local hospital capacity here. To find out more about the hospital capacity dataset, see the full details.

• Pull the 100 counties with the highest per-capita confirmed cases here

• Rank all the counties by the highest per-capita rate of new cases in the past 7 days here. Be aware that because this ranks per-capita caseloads, very small counties may rise to the very top, so take into account raw caseload figures as well.

Interactive

The AP has designed an interactive map to track COVID-19 cases reported by Johns Hopkins.

@(https://datawrapper.dwcdn.net/nRyaf/15/)

Interactive Embed Code

<iframe title="USA counties (2018) choropleth map Mapping COVID-19 cases by county" aria-describedby="" id="datawrapper-chart-nRyaf" src="https://datawrapper.dwcdn.net/nRyaf/10/" scrolling="no" frameborder="0" style="width: 0; min-width: 100% !important;" height="400"></iframe><script type="text/javascript">(function() {'use strict';window.addEventListener('message', function(event) {if (typeof event.data['datawrapper-height'] !== 'undefined') {for (var chartId in event.data['datawrapper-height']) {var iframe = document.getElementById('datawrapper-chart-' + chartId) || document.querySelector("iframe[src*='" + chartId + "']");if (!iframe) {continue;}iframe.style.height = event.data['datawrapper-height'][chartId] + 'px';}}});})();</script>

Caveats

• This data represents the number of cases and deaths reported by each state and has been collected by Johns Hopkins from a number of sources cited on their website.
• In some cases, deaths or cases of people who've crossed state lines -- either to receive treatment or because they became sick and couldn't return home while traveling -- are reported in a state they aren't currently in, because of state reporting rules.
• In some states, there are a number of cases not assigned to a specific county -- for those cases, the county name is "unassigned to a single county"
• This data should be credited to Johns Hopkins University's COVID-19 tracking project. The AP is simply making it available here for ease of use for reporters and members.
• Caseloads may reflect the availability of tests -- and the ability to turn around test results quickly -- rather than actual disease spread or true infection rates.
• Population estimates at the county level are drawn from 2014-18 5-year estimates from the American Community Survey.
• The Urban/Rural classification scheme is from the Center for Disease Control and Preventions's National Center for Health Statistics. It puts each county into one of six categories -- from Large Central Metro to Non-Core -- according to population and other characteristics. More details about the classifications can be found here.

Johns Hopkins timeseries data - Johns Hopkins pulls data regularly to update their dashboard. Once a day, around 8pm EDT, Johns Hopkins adds the counts for all areas they cover to the timeseries file. These counts are snapshots of the latest cumulative counts provided by the source on that day. This can lead to inconsistencies if a source updates their historical data for accuracy, either increasing or decreasing the latest cumulative count. - Johns Hopkins periodically edits their historical timeseries data for accuracy. They provide a file documenting all errors in their timeseries files that they have identified and fixed here

Attribution

This data should be credited to Johns Hopkins University COVID-19 tracking project

As of March 10, 2023, the state with the highest rate of COVID-19 cases was Rhode Island followed by Alaska. Around 103.9 million cases have been reported across the United States, with the states of California, Texas, and Florida reporting the highest numbers of infections.

From an epidemic to a pandemic The World Health Organization declared the COVID-19 outbreak as a pandemic on March 11, 2020. The term pandemic refers to multiple outbreaks of an infectious illness threatening multiple parts of the world at the same time; when the transmission is this widespread, it can no longer be traced back to the country where it originated. The number of COVID-19 cases worldwide is roughly 683 million, and it has affected almost every country in the world.

The symptoms and those who are most at risk Most people who contract the virus will suffer only mild symptoms, such as a cough, a cold, or a high temperature. However, in more severe cases, the infection can cause breathing difficulties and even pneumonia. Those at higher risk include older persons and people with pre-existing medical conditions, including diabetes, heart disease, and lung disease. Those aged 85 years and older have accounted for around 27 percent of all COVID deaths in the United States, although this age group makes up just two percent of the total population

As of March 10, 2023, the death rate from COVID-19 in the state of New York was 397 per 100,000 people. New York is one of the states with the highest number of COVID-19 cases.

View daily updates and historical trends for US Coronavirus Deaths Per Day. from United States. Source: Johns Hopkins Center for Systems Science and Engin…

As of January 6, 2022, an average of 1,192 people per day have died from COVID-19 in the U.S. since the first case was confirmed in the country on January 20th the year before. On an average day, nearly 8,000 people die from all causes in the United States, based on data from 2019. Based on the latest information, roughly one in seven deaths each day were related to COVID-19 between January 2020 and January 2022. However, there were even days when more than every second death in the U.S. was connected to COVID-19. The daily death toll from the seasonal flu, using preliminary maximum estimates from the 2019-2020 influenza season, stood at an average of around 332 people. We have to keep in mind that a comparison of influenza and COVID-19 is somewhat difficult. COVID-19 cases and deaths are counted continuously since the begin of the pandemic, whereas flue counts are seasonal and often less accurate. Furthermore, during the last two years, COVID-19 more or less 'replaced' the flu, with COVID-19 absorbing potential flu cases. Many countries reported a very weak seasonal flu activity during the COVID-19 pandemic. But it has yet to be seen how the two infectious diseases will develop side by side during the winter season 2021/2022 and in the years to come.

Symptoms and self-isolation COVID-19 and influenza share similar symptoms – a cough, runny nose, and tiredness – and telling the difference between the two can be difficult. If you have minor symptoms, there is no need to seek urgent medical care, but it is recommended that you self-isolate, whereas rules vary from country to country. Additionally, rules depend on someone's vaccination status and infection history. However, if you think you have the disease, a diagnostic test can show if you have an active infection.

Scientists alert to coronavirus mutations The genetic material of the novel coronavirus is RNA, not DNA. Other notable human diseases caused by RNA viruses include SARS, Ebola, and influenza. A continual problem that vaccine developers encounter is that viruses can mutate, and a treatment developed against a certain virus type may not work on a mutated form. The seasonal flu vaccine, for example, is different each year because influenza viruses are frequently mutating, and it is critical that those genetic changes continue to be tracked.

February 2nd Update

The AP has requested a timeseries dataset reporting daily counts for distributed and administered vaccines in the U.S. from the CDC. In the absence of that dataset, we are storing daily snapshots of the cumulative counts provided by the CDC COVID Data Tracker and compiling a timeseries dataset here. This process has captured cumulative counts going back to January 4th and daily counts of new doses administered and distributed going back to January 5th. The timeseries dataset also includes seven-day rolling average calculations for the daily metrics.

We have identified a few instances of decreasing cumulative counts in this timeseries, which result in single-day negative counts. We are treating these instances as corrections, and include the negative counts in the rolling averages.

We are investigating the cumulative count decreases and will update the timeseries dataset if necessary with additional information from the CDC. When the CDC provides its own timeseries dataset we will make that available here.

Overview

The AP is using data provided by the Centers for Disease Control and Prevention to report vaccine doses distributed and administered in the United States.

This data is from the CDC's COVID Data Tracker, which is updated daily. However, keep in mind that healthcare providers can report doses to federal, state, territorial, and local agencies up to 72 hours after doses are administered.

To learn more about AP's data journalism capabilities for publishers, corporations and financial institutions, go here or email kromano@ap.org.

Interactive

The AP has designed an interactive map to track COVID-19 vaccine counts reported by The CDC. @(https://interactives.ap.org/embeds/TUVpf/14/)

Interactive Embed Code

<iframe title="Tracking US COVID vaccinations" aria-label="Map" id="datawrapper-chart-TUVpf" src="https://interactives.ap.org/embeds/TUVpf/14/" scrolling="no" width="100%" style="border:none" height="548"></iframe><script type="text/javascript">!function(){"use strict";window.addEventListener("message",(function(a){if(void 0!==a.data["datawrapper-height"])for(var e in a.data["datawrapper-height"]){var t=document.getElementById("datawrapper-chart-"+e)||document.querySelector("iframe[src*='"+e+"']");t&&(t.style.height=a.data["datawrapper-height"][e]+"px")}}))}();</script>

Caveats

From The CDC: - Numbers reported on CDC’s website are validated through a submission process with each jurisdiction and may differ from numbers posted on other websites. - Differences between reporting jurisdictions and CDC’s website may occur due to the timing of reporting and website updates. - The process used for reporting doses distributed or people vaccinated displayed by other websites may differ.

Matched high and low altitude county demographics.

To estimate county of residence of Filipinx healthcare workers who died of COVID-19, we retrieved data from the Kanlungan website during the month of December 2020.22 In deciding who to include on the website, the AF3IRM team that established the Kanlungan website set two standards in data collection. First, the team found at least one source explicitly stating that the fallen healthcare worker was of Philippine ancestry; this was mostly media articles or obituaries sharing the life stories of the deceased. In a few cases, the confirmation came directly from the deceased healthcare worker's family member who submitted a tribute. Second, the team required a minimum of two sources to identify and announce fallen healthcare workers. We retrieved 86 US tributes from Kanlungan, but only 81 of them had information on county of residence. In total, 45 US counties with at least one reported tribute to a Filipinx healthcare worker who died of COVID-19 were identified for analysis and will hereafter be referred to as “Kanlungan counties.” Mortality data by county, race, and ethnicity came from the National Center for Health Statistics (NCHS).24 Updated weekly, this dataset is based on vital statistics data for use in conducting public health surveillance in near real time to provide provisional mortality estimates based on data received and processed by a specified cutoff date, before data are finalized and publicly released.25 We used the data released on December 30, 2020, which included provisional COVID-19 death counts from February 1, 2020 to December 26, 2020—during the height of the pandemic and prior to COVID-19 vaccines being available—for counties with at least 100 total COVID-19 deaths. During this time period, 501 counties (15.9% of the total 3,142 counties in all 50 states and Washington DC)26 met this criterion. Data on COVID-19 deaths were available for six major racial/ethnic groups: Non-Hispanic White, Non-Hispanic Black, Non-Hispanic Native Hawaiian or Other Pacific Islander, Non-Hispanic American Indian or Alaska Native, Non-Hispanic Asian (hereafter referred to as Asian American), and Hispanic. People with more than one race, and those with unknown race were included in the “Other” category. NCHS suppressed county-level data by race and ethnicity if death counts are less than 10. In total, 133 US counties reported COVID-19 mortality data for Asian Americans. These data were used to calculate the percentage of all COVID-19 decedents in the county who were Asian American. We used data from the 2018 American Community Survey (ACS) five-year estimates, downloaded from the Integrated Public Use Microdata Series (IPUMS) to create county-level population demographic variables.27 IPUMS is publicly available, and the database integrates samples using ACS data from 2000 to the present using a high degree of precision.27 We applied survey weights to calculate the following variables at the county-level: median age among Asian Americans, average income to poverty ratio among Asian Americans, the percentage of the county population that is Filipinx, and the percentage of healthcare workers in the county who are Filipinx. Healthcare workers encompassed all healthcare practitioners, technical occupations, and healthcare service occupations, including nurse practitioners, physicians, surgeons, dentists, physical therapists, home health aides, personal care aides, and other medical technicians and healthcare support workers. County-level data were available for 107 out of the 133 counties (80.5%) that had NCHS data on the distribution of COVID-19 deaths among Asian Americans, and 96 counties (72.2%) with Asian American healthcare workforce data. The ACS 2018 five-year estimates were also the source of county-level percentage of the Asian American population (alone or in combination) who are Filipinx.8 In addition, the ACS provided county-level population counts26 to calculate population density (people per 1,000 people per square mile), estimated by dividing the total population by the county area, then dividing by 1,000 people. The county area was calculated in ArcGIS 10.7.1 using the county boundary shapefile and projected to Albers equal area conic (for counties in the US contiguous states), Hawai’i Albers Equal Area Conic (for Hawai’i counties), and Alaska Albers Equal Area Conic (for Alaska counties).20

The National Social Life, Health and Aging Project (NSHAP) is a population-based study of health and social factors on a national scale, aiming to understand the well-being of older, community-dwelling Americans by examining the interactions among physical health, illness, medication use, cognitive function, emotional health, sensory function, health behaviors, and social connectedness. It is designed to provide health providers, policy makers, and individuals with useful information and insights into these factors, particularly on social and intimate relationships. The National Opinion Research Center (NORC), along with Principal Investigators at the University of Chicago, conducted more than 3,000 interviews during 2005 and 2006 with a nationally representative sample of adults aged 57 to 85. Face-to-face interviews and biomeasure collection took place in respondents' homes. Round 3 was conducted from September 2015 through November 2016, where 2,409 surviving Round 2 respondents were re-interviewed, and a New Cohort consisting of adults born between 1948 and 1965 together with their spouses or co-resident partners was added. All together, 4,777 respondents were interviewed in Round 3. The following files constitute Round 3: Core Data, Social Networks Data, Disposition of Returning Respondent Partner Data, and Proxy Data. Included in the Core files (Datasets 1 and 2) are demographic characteristics, such as gender, age, education, race, and ethnicity. Other topics covered respondents' social networks, social and cultural activity, physical and mental health including cognition, well-being, illness, history of sexual and intimate partnerships and patient-physician communication, in addition to bereavement items. In addition data on a panel of biomeasures including, weight, waist circumference, height, and blood pressure was collected. The Social Networks (Datasets 3 and 4) files detail respondents' current relationship status with each person identified on the network roster. The Disposition of Returning Respondent Partner (Datasets 5 and 6) files detail information derived from Section 6A items regarding the partner from Rounds 1 and 2 within the questionnaire. This provides a complete history for respondent partners across both rounds. The Proxy (Datasets 7 and 8) files contain final health data for Round 1 and Round 2 respondents who could not participate in NSHAP due to disability or death. The COVID-19 sub-study, administered to NSHAP R3 respondents in the Fall of 2020, was a brief self-report questionnaire that probed how the coronavirus pandemic changed older adults' lives. The COVID-19 sub-study questionnaire was limited to assessing specific domains in which respondents may have been affected by the coronavirus pandemic, including: (1) COVID experiences, (2) health and health care, (3) job and finances, (4) social support, (5) marital status and relationship quality, (6) social activity and engagement, (7) living arrangements, (8) household composition and size, (9) mental health, (10) elder mistreatment, (11) health behaviors, and (12) positive impacts of the coronavirus pandemic. Questions about engagement in racial justice issues since the death of George Floyd in police custody were also added to facilitate analysis of the independent and compounding effects of both the COVID-19 pandemic and reckoning with longstanding racial injustice in America.

Between the beginning of January 2020 and June 14, 2023, of the 1,134,641 deaths caused by COVID-19 in the United States, around 307,169 had occurred among those aged 85 years and older. This statistic shows the number of coronavirus disease 2019 (COVID-19) deaths in the U.S. from January 2020 to June 2023, by age.

Percentage of recovered and death rates in COVID-19 patients.

Severe Acute Respiratory Syndrome Coronavirus SARS Nucleic Acid Detection Kit Market Outlook 2032

The global severe acute respiratory syndrome coronavirus SARS nucleic acid detection kit market size was USD XX Billion in 2023 and is projected to reach USD XX Billion by 2032, expanding at a CAGR of XX% during 2024–2032. The market growth is attributed to the increasing awareness of SARS across the globe.



Growing awareness of SARS boosts the market. Rising awareness and understanding of severe acute respiratory syndrome (SARS) among healthcare professionals and the general public is a significant driver of the market. This heightened awareness has been stimulated by the global impact of the COVID-19 pandemic, which has highlighted the importance of early detection and accurate diagnosis of respiratory viruses.

Impact of Artificial Intelligence (AI) in Severe Acute Respiratory Syndrome Coronavirus SARS Nucleic Acid Detection Kit Market

The advent of Artificial Intelligence (AI) has significantly transformed the severe acute respiratory syndrome coronavirus (SARS) nucleic acid detection kit market. AI has enhanced the speed, efficiency, and accuracy of diagnosing SARS, improving patient outcomes and reducing healthcare costs. It has enabled the development of sophisticated algorithms that analyze complex biological data and detect the presence of the virus in a patient's sample with high precision.



AI has facilitated the automation of the testing process, thereby increased the testing capacity and reduced the turnaround time. It has improved the predictive capabilities of these kits, enabling healthcare professionals to identify potential SARS cases early and initiate timely treatment.

AI has fostered the development of advanced detection kits that differentiate SARS from other respiratory infections, thereby reducing false positives and negatives. Therefor

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Outlook 2032

The global human immunoglobulin (pH4) for intravenous injection (COVID-19) market size was USD XX Billion in 2023 and is likely to reach USD XX Billion by 2032, expanding at a CAGR of XX% during 2024–2032. The market is propelled by the heightened awareness regarding COVID infection among people globally.



Increasing recognition of the therapeutic potential of human immunoglobulin (pH4) for intravenous injection in treating COVID-19 is projected to fuel the market during the assessment period. This treatment utilizes concentrated antibodies derived from the plasma of recovered COVID-19 patients, offering a passive immunization strategy to combat the virus. The latest market trends indicate a surge in demand for these immunoglobulins, driven by their potential to provide immediate immunity for high-risk populations and healthcare workers. This has led to accelerated regulatory approvals and expanded manufacturing capabilities to meet global needs.

Growing evidence of efficacy in reducing the severity of COVID-19 symptoms has expanded the applications of human immunoglobulin (pH4). Hospitals and healthcare facilities are increasingly adopting this treatment for early intervention in cases where patients are at a high risk of developing severe complications. This proactive approach helps in managing hospital resources effectively by potentially reducing the duration of hospital stays and the need for intensive care, thereby alleviating the burden on healthcare systems.



Rising collaboration between biopharmaceutical companies, governments, and global health organizations is fostering the development and distribution of human immunoglobulin (pH4) treatments. These partnerships are crucial for conducting large-scale clinical trials to further validate the efficacy and safety of the treatment, enhancing its credibility and acceptance in the medical community. Additionally, joint efforts are focusing on establishing equitable distribution frameworks to ensure that low-resource regions also gain access to this critical treatment, highlighting the global commitment to combating the pandemic comprehensively.

Impact of Artificial Intelligence (AI) in Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market

Correlation between the altitude and the incidence of COVID-19 in American countries.

Estimated percentage of undiagnosed COVID-19 cases in five American countries.

All of us like to find a way to end Covid 19. Specially, economy confronts with many problems. In attached JPG, i bring two predictions for covid 19 pandemic in Iran. Mathematical model predicts that after a fall in figure we will have a peak. However, right now, most of people in Iran used of vaccines. In addition, government forced on all to get vaccine. Even, students with 12 to 18 years old get vaccine. It has been heard that soonly, kids with ages between 3-12 years old will receive vaccine. As a man or woman, all of us like that this program will response and vaccines work. However, predictions of math show reverse result. Although, maybe, we should enter the factor of vaccine in mathematical model. It is good opportunity for scientists to examine response of covid 19 to program of vaccine for all. Even if we have a peak, however its height be smaller, we can say that vaccines act. Hope for ending Covid 19 in all countries.